MedTrace Logo

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-01-31

No results posted yet for this study

Summary

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Conditions

Interventions

DRUG

NIS793

Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.

DRUG

PDR001

Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-25
Primary Completion
2021-06-18
Completion
2021-06-18
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Switzerland
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02947165 on ClinicalTrials.gov